🔍 Diasorin & Thermo Fisher Sign Exclusive U.S. Distribution Deal — A Major Move in Rapid Molecular POC Expansion

Diasorin has entered an exclusive U.S. hospital‑channel distribution agreement with Fisher Scientific (Thermo Fisher Scientific) to commercialize the Liaison NES rapid molecular point‑of‑care system, following its recent FDA 510(k) clearance and CLIA waiver for the 15‑minute Flu A/B, RSV, and SARS‑CoV‑2 panel. The partnership immediately strengthens Diasorin’s reach across 7,000+ U.S. hospitals and sets the stage for additional agreements targeting the 130,000‑site physician office lab (POL) market.

---

📌 Key Highlights from the Press Release

1. Exclusive U.S. Hospital Distribution via Thermo Fisher

• Fisher Scientific will distribute the Liaison NES platform across U.S. hospitals.
• This accelerates Diasorin’s penetration into large Integrated Delivery Networks (IDNs).

2. Recently Cleared 4‑Plex Respiratory Panel

• Detects Flu A, Flu B, RSV, and SARS‑CoV‑2.
• Delivers PCR‑quality results in ~15 minutes using a simple three‑step workflow.

3. Expansion Beyond Hospitals

• Diasorin is finalizing additional distribution agreements to reach the non‑acute POL segment (130,000+ sites).
• NES is positioned to compete with other sub‑20‑minute molecular systems like bioMérieux SpotFire and Nuclein Dash.

4. Strengthened U.S. Commercial Footprint

• Diasorin has expanded its dedicated NES salesforce.
• Thermo Fisher’s footprint complements Diasorin’s existing MDX and PLEX molecular portfolio.

---

📈 What This Means for the POC Molecular Market

This agreement signals a major competitive escalation in rapid molecular diagnostics:
- NES now has immediate access to the largest hospital distribution network in the U.S.
- The combination of CLIA waiver + rapid PCR + strong channel partners positions NES as a credible challenger to incumbents like Cepheid, Abbott, Roche, and BD.
- The push into POLs and decentralized care aligns with broader market shifts toward near‑patient molecular testing.

---

📘 GRN IVD Consulting — Your Strategic Lens on the POC Market

The Diasorin–Thermo Fisher partnership underscores exactly why diagnostics companies, investors, and BD teams need clear, data‑driven insight into the evolving POC landscape.

The GRN IVD Consulting Point‑of‑Care Market Report provides:
- Market sizing & growth forecasts across respiratory, molecular, and decentralized testing segments
- Competitive intelligence on platforms like NES, ID NOW, Liat, GeneXpert Xpress, SpotFire, Dash, and more
- Channel strategy analysis (hospital, retail, POL, urgent care)
- Workflow, menu, and regulatory comparisons across leading POC systems
- Actionable recommendations for commercial, BD, and investment teams

If your organization needs to understand where POC molecular is heading and how to position for growth, this report delivers the clarity and strategic depth required.

Download our Point-of-Care Market Report or contact us to tailor insights for your 2026 planning.